BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep 2018;41. [PMID: 30239930 DOI: 10.1093/sleep/zsy185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Li X, Yang S, Wang T, Xu Z, Xu J, Gao H, Chen G. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials. Pharmacol Res 2021;167:105522. [PMID: 33667687 DOI: 10.1016/j.phrs.2021.105522] [Reference Citation Analysis]
2 Guevarra JT, Hiensch R, Varga AW, Rapoport DM. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility. Nat Sci Sleep 2020;12:709-19. [PMID: 33117007 DOI: 10.2147/NSS.S264140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials. Sleep Med 2020;75:510-21. [PMID: 33032062 DOI: 10.1016/j.sleep.2020.09.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lamb YN. Pitolisant: A Review in Narcolepsy with or without Cataplexy. CNS Drugs 2020;34:207-18. [PMID: 31997137 DOI: 10.1007/s40263-020-00703-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
5 Årnes M, Bachs L, Sammarai MA, Jones AW, Høiseth G. Rate of elimination of γ-hydroxybutyrate from blood determined by analysis of two consecutive samples from apprehended drivers in Norway. Forensic Sci Int 2020;314:110374. [PMID: 32604006 DOI: 10.1016/j.forsciint.2020.110374] [Reference Citation Analysis]
6 Sivam S, Chamula K, Swieca J, Frenkel S, Saini B. Narcolepsy management in Australia: time to wake up. Med J Aust 2021;215:62-63.e1. [PMID: 34145573 DOI: 10.5694/mja2.51150] [Reference Citation Analysis]
7 Lehert P, Szoeke C. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach. Drugs Context 2020;9:2020-6-2. [PMID: 32699548 DOI: 10.7573/dic.2020-6-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Parmar A, Murray BJ, Narang I. Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy. Curr Neurol Neurosci Rep 2020;20:38. [PMID: 32651734 DOI: 10.1007/s11910-020-01057-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, Khatami R, Koning F, Kornum BR, Lammers GJ, Liblau RS, Luppi PH, Mayer G, Pollmächer T, Sakurai T, Sallusto F, Scammell TE, Tafti M, Dauvilliers Y. Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 2019;15:519-39. [DOI: 10.1038/s41582-019-0226-9] [Cited by in Crossref: 113] [Cited by in F6Publishing: 89] [Article Influence: 37.7] [Reference Citation Analysis]
10 Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials. Sleep Med 2021;79:40-7. [PMID: 33472129 DOI: 10.1016/j.sleep.2020.12.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pellitteri G, de Biase S, Valente M, Gigli GL. How treatable is narcolepsy with current pharmacotherapy and what does the future hold? Expert Opin Pharmacother 2021;22:1517-20. [PMID: 33882765 DOI: 10.1080/14656566.2021.1915987] [Reference Citation Analysis]
12 Krahn LE, Zee PC, Thorpy MJ. Current Understanding of Narcolepsy 1 and its Comorbidities: What Clinicians Need to Know. Adv Ther 2022;39:221-43. [PMID: 34894325 DOI: 10.1007/s12325-021-01992-4] [Reference Citation Analysis]
13 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Yang J, Gao J. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Review of Clinical Pharmacology 2019;12:723-8. [DOI: 10.1080/17512433.2019.1632705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC; HARMONY III study group. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep 2019;42:zsz174. [PMID: 31529094 DOI: 10.1093/sleep/zsz174] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]